<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906850</url>
  </required_header>
  <id_info>
    <org_study_id>2021-05Obs-CHRMT</org_study_id>
    <nct_id>NCT04906850</nct_id>
  </id_info>
  <brief_title>Evaluation of the New Variant 501Y.V2 of COVID-19</brief_title>
  <acronym>VARICOVID</acronym>
  <official_title>Comparison of Mortality in Severe SARS-Cov-2 Infection Caused by the 501Y.V2 Variant and B.1.1.7 Variant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional Metz-Thionville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional Metz-Thionville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In January 2021, the incidence of COVID-19-and its mortality started rising for the third&#xD;
      time in France. This rise may associate with three emerging variants, namely, V1, V2, and V3,&#xD;
      which are the 20I/501Y.V1 (&quot;English&quot;), 20H/501Y.V2 (&quot;South African&quot;), and 20J/501Y.V3&#xD;
      (&quot;Brazilian&quot;) variants, respectively. V1 was recently suggested to increase mortality in&#xD;
      people in the United Kingdom who tested positive for COVID-19 on community screening. Very&#xD;
      little is known about V2 infection, including its outcomes relative to other strains. In&#xD;
      early 2021, V2 spread to the Grand-Est region (northeastern France). Here, the investigators&#xD;
      aimed to report mortality data of patients admitted in ICU between February and April 2021 in&#xD;
      3 hospitals in Grand-Est: Metz, Thionville and Nancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality 28 days after admission</measure>
    <time_frame>Day 28</time_frame>
    <description>Vital status 28 days after admission in Intensive Care Unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of mortality in Intensive Care Unit</description>
  </secondary_outcome>
  <enrollment type="Actual">250</enrollment>
  <condition>Covid19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with 20I/501Y.V1 (&quot;English&quot;) or 20H/501Y.V2 (&quot;South African&quot;) SARS-CoV-2 variants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission in ICU in February, March or April 2021&#xD;
&#xD;
          -  Patient with a SARS-CoV-2 positive polymerase-chain reaction test&#xD;
&#xD;
          -  Patient with 20I/501Y.V1 (&quot;English&quot;) or 20H/501Y.V2 (&quot;South African&quot;) SARS-CoV-2&#xD;
             variants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposed to use data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-moselle</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Metz Thionville</name>
      <address>
        <city>Metz</city>
        <state>Moselle</state>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mortality</keyword>
  <keyword>SARS-CoV-2 variants</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>20I/501Y.V1</keyword>
  <keyword>20H/501Y.V2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

